Stocks Hitting 52-Week Highs

shares reached a new 52-week high of $27.62 after

, in cooperation with Neurocrine Biosciences, announced positive top-line results from Phase 3 study of investigational medicine elagolix.

shares touched a new 52-week high of $35 after the company reported the FDA approval of RYTARY ER-capsules for the treatment of parkinson's disease.

shares touched a new 52-week high of $67.96. Macy's PEG ratio is 1.19.

shares climbed 4.76% to reach a new 52-week high of $107.96 after the company reported upbeat earnings for the fiscal third quarter and raised its forecast for the full year.